SCHEMBL12188010

SCHEMBL12188010

COc1ccc(-c2nc3ccc(C(=O)O)cc3nc2N2CCOCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP1 P29466 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ NAMPT P43490 9/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ GAA P10253 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ TP53 P04637 1/20 0.48
▸ PIK3CA P42336 2/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ CDH1 P12830 1/20 0.46
▸ APC P25054 1/20 0.46
▸ CTNNB1 P35222 1/20 0.46
▸ TCF7L2 Q9NQB0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188011 0.90 ALDH1A1 (0.52) NAMPTALDH1A1KDM4EGAAHPGD
SCHEMBL12187987 0.89 ALDH1A1 (0.51) NAMPTALDH1A1KDM4EGAAHPGD
SCHEMBL12188012 0.89 ALDH1A1 (0.51) NAMPTALDH1A1KDM4EGAAHPGD
SCHEMBL1458253 0.87 CASP1 (0.70) CASP1HSD17B10NAMPTALDH1A1KDM4E
SCHEMBL1458086 0.87 SIRT1 (0.56) NAMPTALDH1A1KDM4EGAAHPGD
SCHEMBL12187985 0.84 MTOR (0.48) ALDH1A1KDM4EGAAHPGDMAPT
SCHEMBL12164946 0.84 NAMPT (0.54) CASP1HSD17B10NAMPTALDH1A1KDM4E
SCHEMBL12164945 0.82 NAMPT (0.51) CASP1HSD17B10NAMPTALDH1A1KDM4E
SCHEMBL1459068 0.82 CASP1 (0.62) CASP1HSD17B10NAMPTALDH1A1KDM4E
SCHEMBL6227154 0.82 ALDH1A1 (0.71) ALDH1A1KDM4EGAAHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912188-B2 Substituted quinoxaline carboxylic acids for the inhibition of PASK BIOENERGENIX, LLC (US) 2014-12-16 — — US disclosed
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-13 — — US disclosed
WO-2012119046-A2 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK PASK, PDXK, PANK2 CASP1 3195/4885HSD17B10 2554/4885NAMPT 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback